lopinavir/ritonavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 77 Diseases   69 Trials   69 Trials   4434 News 


«12...1718192021222324252627...4546»
  • ||||||||||  Prezista (darunavir) / J&J, Viracept (nelfinavir) / ViiV Healthcare, Roche
    Review, Journal:  Antiretrovirals for prophylaxis against COVID-19; a comprehensive literature review. (Pubmed Central) -  Nov 22, 2020   
    NRTIs like tenofovir and emtricitabine might exhibit prophylactic role against SARS-CoV-2 infection. In conclusion, currently there is no evidence to justify the use of ARVs for prophylaxis against COVID-19.
  • ||||||||||  remdesivir / Generic mfg., ritonavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  Remdesivir versus ritonavir/lopinavir in COVID-19 patients. (Pubmed Central) -  Nov 21, 2020   
    However caution may be advised because human data are limited and the potential risk of embryo-fetal toxicity cannot be excluded. No abstract available
  • ||||||||||  ritonavir / Generic mfg.
    Review, Journal:  Update on COVID-19: A teleconference with the Paediatric Virology Study Group (Review). (Pubmed Central) -  Nov 21, 2020   
    However, the usage of most of these into clinical practice was not based on randomised clinical trials and their results should be viewed with extreme caution; remdesivir seems to be the more promising option. Rigorous efforts are under way for the development of a safe and successful vaccine against SARS-CoV-2.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Clinical, Journal:  Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality. (Pubmed Central) -  Nov 21, 2020   
    The observed association patterns are consistent with previous literature. It seems necessary to design randomized controlled clinical trials that evaluate the possible protector effect of tocilizumab and corticoids in the risk of mortality for some subgroups of COVID-19 hospitalized patients.
  • ||||||||||  Intron A (interferon α-2b) / Merck (MSD), Biogen
    Clinical, Journal:  First patient management of COVID-19 in Changsha, China: a case report. (Pubmed Central) -  Nov 21, 2020   
    Currently, there are numerous reports on COVID-19 infections focusing on the disease's epidemiological and clinical characteristics. This case describes the symptoms, diagnosis, treatment, and management of a patient cured of COVID-19 infection, which may serve as reference for future cases, while further studies are needed.
  • ||||||||||  ritonavir / Generic mfg.
    Journal:  Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach. (Pubmed Central) -  Nov 18, 2020   
    Similar studies were performed with lopinavir and ritonavir coupled to monomeric and dimeric SARS-CoV M and SARS-CoV2 M to compare the inhibitory differences. Our study provides the structural and energetic basis of the inhibitory properties of lopinavir and ritonavir on SARS-CoV M and SARS-CoV2 M, allowing us to identify two FDA-approved drugs that can be used against SARS-CoV2 M. This study also demonstrated that drug discovery requires the dimeric state to obtain good results.
  • ||||||||||  Arbidol (umifenovir) / Pharmstandard
    Retrospective data, Journal:  Retrospective analysis of the effect of current clinical medications and clinicopathological factors on viral shedding in COVID-19 patients. (Pubmed Central) -  Nov 18, 2020   
    Multi-factor regression analysis suggested that the onset-hospitalization interval [odds ratio (OR), 1.27; 95% confidence interval (CI), 1.15-1.41; P<0.001] and comorbidity with a chronic disease (OR, 2.43; 95% CI, 1.14-5.17; P=0.021) were independent risk factors for prolonged viral shedding, whereas lopinavir/ritonavir (LPV/r) was an independent protective factor (OR, 0.28; 95% CI, 0.11-0.75; P=0.011)...Umifenovir, and low and short courses of glucocorticoids were not associated with prolonged viral shedding...The interval between presentation of symptoms and hospitalization as well as complications with a comorbid chronic disease were independent risk factors for prolonged viral shedding. LPV/r shortened the duration of viral shedding, and the smaller the interval between presentation and LPV/r onset was, the faster viral shedding occurred.
  • ||||||||||  Enrollment change:  RECOVERY: Randomised Evaluation of COVID-19 Therapy (clinicaltrials.gov) -  Nov 12, 2020   
    P2/3,  N=20000, Recruiting, 
    Numerous studies demonstrated the ability of remdesivir to inhibit SARS-CoV-2 replication but future research would be needed to understand the exact mode of action of lopinavir/ritonavir and chloroquine/hydroxychloroquine in SARS-CoV-2 infected cells and to use this knowledge in the treatment of the current COVID-19. N=15000 --> 20000
  • ||||||||||  hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Enrollment closed:  Treatment for COVID-19 in High-Risk Adult Outpatients (clinicaltrials.gov) -  Nov 12, 2020   
    P2/3,  N=300, Active, not recruiting, 
    N=15000 --> 20000 Recruiting --> Active, not recruiting
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    [VIRTUAL] Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_3603;    
    29.4% were off-therapy and 70.6% under antileukemic treatment at the time of SARS-CoV-2: induction chemotherapy (25.3%), hypomethylating (19.3%), clinical trial (17.0%), consolidation chemotherapy (14.8%), venetoclax (3.4%), FLT3 inhibitors (3.4%) and/or maintenance (1.1%)...84.2% received specific treatment for coronavirus infection: chloroquine or hydroxychloroquine (82.2%), lopinavir/ritonavir (54.0%), corticosteroids (39.6%), azithromycin (33.0%), tocilizumab (15.8%), plasma convalescent (3.0%), clinical trial medication (3.0%), remdesivir (2.0%) and/or anakinra (1.0%)...Conclusions SARS-CoV-2 infection produces high mortality among AML patients. Mortality was correlated with age, active disease and pneumonia.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    [VIRTUAL] Impact of Sars-Cov-2 Infection in Hematopoietic Transplant Patients: Experience from the Madrid Group (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_2875;    
    23 patients (26%) received anticytokine treatment with tocilizumab (15, 17%) and/or anakinra (8, 9%) and 27 patients (31%) received steroids...COVID-19 related mortality was high in HSCT recipients, significantly higher in allo-transplanted patients. Factors associated to this higher mortality should be further investigated to promptly identify high-risk patients since the pandemic is still highly active worldwide.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    [VIRTUAL] COVID 19 and Hemoglobinopathies: Update of the Italian Experience (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_1735;    
    This experience differs from what has been observed in Iran on a similar series with different severity and mortality and ask for a more in-depth comparison [5]. In conclusion, our data do not indicate increased severity of COVID-19 in Pts with Hemoglobinopathies followed in Specialized Centers.
  • ||||||||||  Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci
    Trial initiation date:  DPART: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy (clinicaltrials.gov) -  Nov 3, 2020   
    P4,  N=190, Not yet recruiting, 
    In conclusion, our data do not indicate increased severity of COVID-19 in Pts with Hemoglobinopathies followed in Specialized Centers. Initiation date: Aug 2020 --> Nov 2020
  • ||||||||||  ritonavir / Generic mfg.
    Clinical, Journal:  Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience. (Pubmed Central) -  Nov 1, 2020   
    Immunosuppressive therapy was modified with a median reduction comprising doses that were 50% cyclosporine and 50% mycophenolate...All hospitalized patients received hydroxychloroquine; 2 patients received ritonavir/lopinavir...Because immunomodulation interaction with the infection seems to be crucial for developing severe forms of the disease, we managed to reduce immunosuppressive therapy by adding medium doses of corticosteroids. Despite the limited number of affected patients, this report suggests that special considerations should be given to treating coronavirus disease in the heart transplant recipient population.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Review, Journal:  Current pharmacological treatments for COVID-19: what's next? (Pubmed Central) -  Oct 30, 2020   
    In conclusion, while waiting for the development of effective preventive measures, such as vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. It is conceivable that very soon their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications.
  • ||||||||||  remdesivir / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients. (Pubmed Central) -  Oct 30, 2020   
    This work provides data on size distribution, osmolarity other than drug chemical stability of a lopinavir/ritonavir extemporaneous preparation prepared by using as drug source the solid dosage form (i.e., tablet) available on the market. The reported data indicate that such preparation is suitable to be delivered through a nasogastric tube, and enough stable for two weeks from the preparation at room temperature.
  • ||||||||||  ritonavir / Generic mfg.
    Journal:  In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2. (Pubmed Central) -  Oct 28, 2020   
    In addition, small molecules with anti-inflammatory actions like Mycophenolic acid (MPA), Pemirolast, Isoniazid and Eriodictyol were also tested...Molecular interactions of Ritonavir, Lopinavir and Remdesivir against SARS-CoV-2 proteins enhanced their potential as a candidate drug for treatment of COVID-19. Eriodictyol had emerged as a new repurposing drug that can be used in COVID-19.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Review, Journal:  COVID-19: A review of the proposed pharmacological treatments. (Pubmed Central) -  Oct 28, 2020   
    These include anti-viral agents (remdesivir, ribavirin, lopinavir-ritonavir, favipiravir, chloroquine, hydroxychloroquine, oseltamivir, umifenovir), immunomodulatory agents (tocilizumab, interferons, plasma transfusions), and adjunctive agents (azithromycin, corticosteroids), among other miscellaneous agents. The mechanisms of action and further pharmacological properties will be explored, with a particular focus on the evidence-based safety and efficacy of each agent.
  • ||||||||||  Review, Journal:  COVID-19 associated complications and potential therapeutic targets. (Pubmed Central) -  Oct 28, 2020   
    There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19.
  • ||||||||||  sirolimus / Generic mfg., ritonavir / Generic mfg.
    Review, Journal:  Applying computer simulations in battling with COVID-19, using pre-analyzed molecular and chemical data to face the pandemic. (Pubmed Central) -  Oct 28, 2020   
    The results indicate promising effects of such compounds to be used in further experimental and clinical trials; Chloroquine, Chloroquine-OH, and Umifenovir as viral entry inhibitors, Remdesivir, Ribavirin, Lopinavir, Ritonavir, and Darunavir as viral replication inhibitors, and Sirolimus are the examples, which were tested clinically on patients after comprehensive assessments of the available data on molecular simulation. This review summarizes the outcomes of various computer simulations data in the battle against COVID-19.